Mizuho initiated coverage on Envista with a new price target
$NVST
Medical/Dental Instruments
Health Care
Mizuho initiated coverage of Envista with a rating of Underperform and set a new price target of $20.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/4/2024 | $20.00 | Underperform | Mizuho |
| 10/31/2024 | $16.00 → $23.00 | Underperform → Market Perform | Leerink Partners |
| 10/8/2024 | $20.00 | Equal Weight | Wells Fargo |
| 8/8/2024 | $23.00 → $16.00 | Overweight → Neutral | JP Morgan |
| 4/26/2024 | $33.00 → $21.00 | Overweight → Equal-Weight | Morgan Stanley |
| 2/26/2024 | $19.00 | Underperform | Leerink Partners |
| 2/9/2024 | $30.00 → $23.00 | Buy → Hold | Jefferies |
| 2/8/2024 | Outperform → Mkt Perform | William Blair |
Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T
QUAKERTOWN, PA / ACCESSWIRE / November 28, 2024 / The latest AI-powered launches from DEXIS enhance diagnostics and patient care. At ADF, DEXIS showcased its innovative product line, including the new intraoral scanners and imaging products. The conference took place November 26-30 at the Palais des Congrès de Paris in Porte Maillot, France. The company's comprehensive range of award-winning solutions covers a complete digital diagnostic workflow, from intraoral scanning and implant planning to sensors, CBCT, and imaging software. With an expanded portfolio and ecosystem, DEXIS Solutions is designed to accelerate workflows, increase productivity, and improve the patient experience."Our techn
BREA, Calif., Nov. 20, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced the release of its 2023 Sustainability Report, outlining its continued efforts to integrate environmental, social, and governance (ESG) considerations into its mission to digitize, personalize, and democratize dental care. The full report can be found HERE. "Our efforts to promote improved environment, social, and governance initiatives are central to how we support our stakeholders. Through the lens of our key areas of focus – Delivering Quality and Access; Supporting Our Peop
BREA, Calif., Oct. 30, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the third quarter of 2024. For the quarter ended September 27, 2024, reported sales were $601.0 million. Core sales in the quarter declined 5.3% over the corresponding quarter in 2023. Net income in the third quarter was $8.2 million or $0.05 per diluted share, compared to net income of $21.5 million or $0.12 per diluted share in Q3 2023. Adjusted net income for the third quarter of 2024 was $21.1 million or $0.12 per diluted share, compared to adjusted net income
BREA, Calif., Oct. 7, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its third quarter 2024 on Wednesday, October 30, 2024. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. Y
BREA, Calif., Aug. 7, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the second quarter of 2024. For the quarter ended June 28, 2024, reported sales were $633.1 million. Core sales in the quarter declined 3.2% over the corresponding quarter in 2023. Net loss in the second quarter was $1,151.6 million or $6.69 per share. The net loss included a $1,153.8 million non-cash charge related to the impairment of goodwill and intangible assets. During the same period, adjusted net income was $18.5 million or $0.11 per diluted share compared
SC 13G - Envista Holdings Corp (0001757073) (Subject)
SC 13G/A - Envista Holdings Corp (0001757073) (Subject)
SC 13G - Envista Holdings Corp (0001757073) (Subject)
8-K - Envista Holdings Corp (0001757073) (Filer)
SCHEDULE 13G - Envista Holdings Corp (0001757073) (Subject)
10-Q - Envista Holdings Corp (0001757073) (Filer)
3 - Envista Holdings Corp (0001757073) (Issuer)
3 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T
WESTPORT, Conn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, announced today that Stephen Keller has been appointed as the Company's Chief Financial Officer (CFO), effective August 31, 2024. He will be replacing Ryan Faulkingham, who has served as the Company's CFO since July 2013 and is departing the Company effective August 30, 2024. Mr. Faulkingham will continue to serve in an advisory capacity in order to facilitate a seamless transition. In his new role, Mr. Keller will lead CODI's finance organization, including accounting, planning, treasury, tax, reporting, and investor relations. He b
BREA, Calif., July 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced the following key leadership appointments: Eric Hammes joins Envista as Chief Financial OfficerStefan Nilsson joins Envista as President, Nobel BiocareVeronica Acurio joins Envista as President, Ormco"It is a pleasure to welcome this trio of successful leaders to Envista," said Paul Keel, Chief Executive Officer. "Each brings experience in dental along with a proven track record of continuous improvement, leading with purpose, and creating value for all stakeholders. Today's an
Mizuho initiated coverage of Envista with a rating of Underperform and set a new price target of $20.00
Leerink Partners upgraded Envista from Underperform to Market Perform and set a new price target of $23.00 from $16.00 previously
Wells Fargo initiated coverage of Envista with a rating of Equal Weight and set a new price target of $20.00
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)